STOCK TITAN

Optimizerx Corp Stock Price, News & Analysis

OPRX Nasdaq

Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.

OptimizeRx Corp (NASDAQ: OPRX) provides a dedicated news hub for tracking developments in healthcare technology and digital patient engagement solutions. This page aggregates official announcements, financial disclosures, and strategic updates from the leader in EHR-integrated pharma messaging.

Investors and industry professionals will find curated coverage of earnings reports, technology partnerships, product launches, and regulatory milestones. The resource serves as a centralized source for understanding OPRX's role in connecting pharmaceutical companies with healthcare providers through cloud-based communication platforms.

Key content categories include financial results, strategic alliances with EHR providers, technology innovations in digital health messaging, and industry recognition of platform advancements. All materials maintain factual accuracy and timeliness required for informed decision-making.

Bookmark this page for streamlined access to OptimizeRx's evolving position in medication adherence solutions and AI-driven healthcare communications. Regular updates ensure stakeholders stay informed about developments impacting the digital pharma marketing landscape.

Rhea-AI Summary

OptimizeRx Corp (Nasdaq: OPRX) announced its participation in three major conferences, including the 42nd Annual William Blair Growth Stock Conference in Chicago from June 6-9, the Stifel 2022 Cross Sector Conference in Boston from June 7-9, and the Roth Capital Partners 8th Annual London Conference from June 21-23. Each event will feature opportunities for management to present and hold one-on-one meetings with investors. OptimizeRx provides critical point-of-care technology solutions to enhance patient therapy adherence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
conferences
-
Rhea-AI Summary

OptimizeRx Corp (Nasdaq: OPRX) announced that Mike Rousselle, its vice president of data product, has been named one of the 2022 PM360 ELITE 100 in the Data Miners category. Rousselle is recognized for his work in applying AI and ML in healthcare marketing, streamlining engagement with healthcare providers at the point-of-care. Steve Silvestro, CCO, highlighted Rousselle's role in driving innovation and efficiency in data solutions for life sciences clients. The PM360 ELITE Awards celebrate influential figures in healthcare, with 100 winners selected from over 500 nominations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.3%
Tags
none
-
Rhea-AI Summary

OptimizeRx Corp (Nasdaq: OPRX) has announced a share repurchase program authorized by its Board of Directors, allowing the company to buy back up to $20 million of its outstanding common stock. CEO Will Febbo indicated this decision reflects the company's commitment to disciplined capital allocation aimed at enhancing shareholder returns. The repurchase aims to strengthen shareholder value while ensuring sufficient working capital for future growth initiatives, including organic growth and potential M&A activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.3%
Tags
buyback
Rhea-AI Summary

OptimizeRx (Nasdaq: OPRX) announced its participation in the RBC Healthcare Conference on May 17-18, 2022, and the B. Riley Annual Institutional Conference on May 25-26, 2022. The company will partake in a fireside chat at the RBC event on May 18 at 2:05 PM ET, and present at the B. Riley conference on May 26 at 9:30 AM PT. Management will also hold one-on-one meetings at both events. OptimizeRx is a leading provider of point-of-care technology that connects patients and healthcare providers to improve medication adherence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
conferences
-
Rhea-AI Summary

OptimizeRx Corp. (Nasdaq: OPRX) reported Q1 2022 revenue of $13.7 million, a 22% increase YoY. Gross profit rose 32% to $8.1 million, with gross margins at 59%. Net loss was $3.8 million or $(0.21) per share. The company completed the acquisition of EvinceMed and maintains a strong cash position of $89.0 million. OPRX reaffirms its 2022 revenue outlook of $80 million to $85 million, targeting 31% to 39% growth. The firm is experiencing positive cash flow from operations with a focus on growth through expanding client engagement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.54%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
Rhea-AI Summary

OptimizeRx Corp (Nasdaq: OPRX) announces a conference call on May 4, 2022, at 4:30 p.m. Eastern Time to discuss its first-quarter financial results for the period ending March 31, 2022. A press release with the financial results will precede the call. Participants can join by telephone or webcast, with a replay available for 12 months on the company’s website. OptimizeRx provides point-of-care technology solutions, connecting healthcare providers and patients to enhance medication adherence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none

FAQ

What is the current stock price of Optimizerx (OPRX)?

The current stock price of Optimizerx (OPRX) is $13.43 as of July 3, 2025.

What is the market cap of Optimizerx (OPRX)?

The market cap of Optimizerx (OPRX) is approximately 234.0M.
Optimizerx Corp

Nasdaq:OPRX

OPRX Rankings

OPRX Stock Data

233.96M
15.60M
6.42%
65.68%
7.64%
Health Information Services
Services-business Services, Nec
Link
United States
WALTHAM